Study does not find increased risk of blood clot following HPV vaccination

July 8, 2014

Although some data has suggested a potential association between receipt of the quadrivalent human papillomavirus (HPV) vaccination and subsequent venous thromboembolism (VTE; blood clot), an analysis that included more than 500,000 women who received the vaccine did not find an increased risk of VTE, according to a study in the July 9 issue of JAMA.

"Safety concerns can compromise to the detriment of public health, and timely evaluations of such concerns are essential," the authors write.

Nikolai Madrid Scheller, M.B., of Statens Serum Institut, Copenhagen, Denmark, and colleagues used data from Danish national registers to evaluate the potential link between quadrivalent HPV vaccination and VTE. Information on vaccination, use of , use of anticoagulants (blood thinners), and the outcome of a first hospital diagnosis of VTE not related to pregnancy, surgery, or cancer was obtained from Danish registers.

The study included all Danish women, ages 10 through 44 years, from October 2006 through July 2013 (n = 1,613,798), including 500,345 (31 percent) who received the quadrivalent HPV vaccine; there were 4,375 incident cases of VTE. Of these, 889 women (20 percent) were vaccinated during the study period. Analysis of the data did not find an association between the quadrivalent HPV vaccine and VTE during the 42 days following vaccination (defined as the main risk period).

"Our results, which were consistent after adjustment for oral contraceptive use and in girls and young women as well as mid-adult women, do not provide support for an increased risk of VTE following quadrivalent HPV vaccination," the researchers write.

Explore further: Study confirms some contraceptive pills more likely to cause blood clots

More information: DOI: 10.1001/jama.2014.2198

Related Stories

VTE risk varies by hormone therapy formulation

September 18, 2012

(HealthDay)—The risk of venous thromboembolism (VTE) in postmenopausal women differs considerably according to the formulation of hormone therapy (HT) used, with the highest VTE risk seen in users of oral estrogen-progestin ...

Recommendations issued to prevent VTE in maternal patients

December 11, 2013

(HealthDay)—The Physician-Patient Alliance for Health & Safety, the Institute for Healthcare Improvement, and the National Perinatal Association have developed safety recommendations aimed at preventing venous thromboembolism ...

Researchers find moral beliefs barrier to HPV vaccine

July 7, 2014

A survey of first-year Grand Valley State University students showed the biggest barrier to receiving a Human Papillomavirus (HPV) vaccine was moral or religious beliefs, or a perceived promotion of sexual behavior, according ...

Recommended for you

Cellphone data can track infectious diseases

August 20, 2015

Tracking mobile phone data is often associated with privacy issues, but these vast datasets could be the key to understanding how infectious diseases are spread seasonally, according to a study published in the Proceedings ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.